全文获取类型
收费全文 | 21514篇 |
免费 | 2129篇 |
国内免费 | 419篇 |
专业分类
耳鼻咽喉 | 118篇 |
儿科学 | 456篇 |
妇产科学 | 545篇 |
基础医学 | 1238篇 |
口腔科学 | 950篇 |
临床医学 | 2917篇 |
内科学 | 3503篇 |
皮肤病学 | 413篇 |
神经病学 | 1414篇 |
特种医学 | 257篇 |
外国民族医学 | 3篇 |
外科学 | 2064篇 |
综合类 | 1788篇 |
一般理论 | 3篇 |
预防医学 | 2008篇 |
眼科学 | 188篇 |
药学 | 3085篇 |
5篇 | |
中国医学 | 1615篇 |
肿瘤学 | 1492篇 |
出版年
2024年 | 65篇 |
2023年 | 599篇 |
2022年 | 656篇 |
2021年 | 1257篇 |
2020年 | 1098篇 |
2019年 | 1104篇 |
2018年 | 1084篇 |
2017年 | 1015篇 |
2016年 | 868篇 |
2015年 | 845篇 |
2014年 | 1654篇 |
2013年 | 2368篇 |
2012年 | 1203篇 |
2011年 | 1176篇 |
2010年 | 954篇 |
2009年 | 932篇 |
2008年 | 989篇 |
2007年 | 924篇 |
2006年 | 848篇 |
2005年 | 703篇 |
2004年 | 610篇 |
2003年 | 489篇 |
2002年 | 430篇 |
2001年 | 308篇 |
2000年 | 251篇 |
1999年 | 219篇 |
1998年 | 182篇 |
1997年 | 186篇 |
1996年 | 133篇 |
1995年 | 104篇 |
1994年 | 116篇 |
1993年 | 81篇 |
1992年 | 75篇 |
1991年 | 64篇 |
1990年 | 59篇 |
1989年 | 82篇 |
1988年 | 56篇 |
1987年 | 47篇 |
1986年 | 24篇 |
1985年 | 39篇 |
1984年 | 33篇 |
1983年 | 26篇 |
1982年 | 18篇 |
1981年 | 16篇 |
1980年 | 12篇 |
1979年 | 18篇 |
1978年 | 10篇 |
1977年 | 7篇 |
1975年 | 6篇 |
1973年 | 7篇 |
排序方式: 共有10000条查询结果,搜索用时 78 毫秒
101.
醒脑静注射液治疗缺血性中风急性期随机对照试验的系统评价 总被引:1,自引:0,他引:1
目的 系统评价醒脑静注射液治疗缺血性中风急性期的疗效及安全性。方法 集醒脑静注射液治疗缺血性中风急性期随机对照试验文献,筛选合格研究,应用Jadad评分法进行质量评价,运用异质性检验、Meta-分析、漏斗图分析、敏感性分析等方法统计相关数据。结果 项研究符合纳入标准,Jadad评分所有研究得分均低于3分,属低质量文献。Meta-分析结果显示,总有效率比较的相对危险度(RR值)=1.04,99%的可信区间(CI值)为(0.88,1.23)。结论 前尚无充分证据证实醒脑静注射液治疗缺血性中风急性期的疗效及安全性。要进一步验证醒脑静注射液治疗缺血性中风急性期的疗效及安全性,尚需进行设计合理、执行严格、多中心大样本且随访时间足够的随机对照试验。 相似文献
102.
Kenji Nakashima M.D. Kazuro Takahashi M.D. 《Psychiatry and clinical neurosciences》1988,42(2):297-306
Abstract: The distribution of somatosensory evoked potentials (SEPs) after stimulation of the median nerve at the wrist was examined in 10 normal subjects using isopotential maps. The latencies of continuous negative and positive peaks were measured in each lead. The differences of the potentials at these latencies were measured in all the leads and the isopotential maps were constructed. The distribution of P0–NI was all similar. The latencies of P0 were almost the same in all the leads at about 13 msec. The distribution of NI-PI-NII was divided into three types—N16–P20–N28 localized in the frontal region, N17–P22–N30 localized in the central region and N19–P25–N33 distributed in the parieto-occipito-temporal regions. The distributions of NII-PII and PII-NIII were all similar, with high amplitudes in the central region. The latencies of PII and NIII were almost the same in all the leads at about 45 msec and 68 msec. 相似文献
103.
Pharmaceutical Research - 相似文献
104.
C S Cleeland R K Portenoy M Rue T R Mendoza E Weller R Payne J Kirshner J N Atkins P A Johnson A Marcus 《Annals of oncology》2005,16(6):972-980
BACKGROUND: Cancer pain is highly prevalent and commonly undertreated. This study was designed to determine whether dissemination of a clinical protocol for pain management would improve outcomes in community oncology practices. PATIENTS AND METHODS: A pain management protocol was developed based on accepted guidelines. After baseline assessment, oncology practices were randomly assigned to 'analgesic protocol' (AP) sites, where oncologists implemented the guidelines in a group of lung or prostate cancer patients, or to 'physician discretion' (PD) sites, where customary treatment was continued. Patients treated on protocol and a comparison group of patients with pain due to breast cancer or myeloma were monitored for change in pain using the Brief Pain Inventory, and for change in other symptoms or mood. RESULTS: The protocol terminated early because of poor accrual. We compared groups using proportions of patients who had no or mild pain at follow-up. Although measures of protocol adherence did not suggest the occurrence of major practice change, the proportion of lung or prostate cancer patients with no or mild pain increased significantly from baseline for those treated at AP sites compared with those treated at PD sites. There was no significant difference between the breast and myeloma patients treated at AP sites versus those treated at PD sites. CONCLUSION: A protocol for cancer pain management can improve pain control. Diffusion of these benefits to other patients was not confirmed. Given the small sample size, these findings require confirmation in a larger trial. 相似文献
105.
国产注射用盐酸瑞芬太尼有效性和安全性的评价 总被引:252,自引:4,他引:248
目的 采用随机、对照、双盲、多中心的Ⅱ期临床试验,评价国产注射用盐酸瑞芬太尼的有效性和安全性。方法201名受试者分成两组:对照组使用静脉芬太尼(2.5μkg诱导,0.03μg·kg-1·min-1维持)复合吸入66%氧化亚氮麻醉,试验组使用静脉瑞芬太尼(2μg/kg诱导,0.2μ·kg-1·min-1维持)复合吸入66%氧化亚氮麻醉。药物有效性的观察指标有:手术刺激时的应激反应,如血压、心率、流泪、麻醉质量。安全性的观察指标有:血压和心率、麻黄碱、阿托品、纳洛酮、乌拉地尔的使用量、手术失血量、心电图变化、术前和术后48 h内血中ALT、AST、肌酐、尿素氮、停止麻醉到可以拔除气管导管的时间、拔除气管导管前的PETCO2或PaCO2、停止麻醉(关闭氧化亚氮)后呼唤名字可以睁眼时间、术后送往麻醉恢复室或ICU情况以及不良事件。结果 瑞芬太尼与芬太尼在本试验剂量下,药效作用相似,但镇痛作用瑞芬太尼强于芬太尼,停止输注后其作用消退快于芬太尼。结论 国产瑞芬太尼用于全麻可产生良好的镇痛作用,且具有与芬太尼相同的安全性。 相似文献
106.
John L. Adams Matthias Schonlau José J. Escarce Meredith Kilgore Michael Schoenbaum Dana P. Goldman 《Health services & outcomes research methodology》2003,4(3):151-167
In order to better inform study design decisions when sampling patients within and across health care providers we develop a simulation-based approach for designing complex multi-stage samples. The approach explores the tradeoff between competing design goals such as precision of estimates, coverage of the target population and cost.We elicit a number of sensible candidate designs, evaluate these designs with respect to multiple sampling goals, investigate their tradeoffs, and identify the design that is the best compromise among all goals. This approach recognizes that, in the practice of sampling, precision of the estimates is not the only important goal, and that there are tradeoffs with coverage and cost that should be explicitly considered. One can easily add other goals. We construct a sample frame with all phase III clinical cancer treatment trials that are conducted by cooperative oncology groups of the National Cancer Institute from October 1, 1998 through December 31, 1999. Simulation results for our study suggest sampling a different number of trials and institutions than initially considered.Simulations of different study designs can uncover efficiency gains both in terms of improved precision of the estimates and in terms of improved coverage of the target population. Simulations enable us to explore the tradeoffs between competing sampling goals and to quantify these efficiency gains. This is true even for complex designs where the stages are not strictly nested in one another. 相似文献
107.
异丙酚及氯胺酮靶控输注全静脉麻醉临床应用 总被引:4,自引:1,他引:3
目的 研究异丙酚复合不同镇痛剂量氯胺酮靶控输注全静脉麻醉临床应用的可行性及对血流动力学、麻醉恢复的影响。方法 择期手术患者 80例 ,分别采用异丙酚 (P组 ,n =16)及复合氯胺酮血药浓度 0 2 0mg/L(PK1组 ,n =16) ,0 40mg/L(PK2 组 ,n =16) ,0 60mg/L(PK3 组 ,n =16)和 0 80mg/L(PK4组 ,n =16)全静脉麻醉 ,采用微机控制Graseby 3 5 0 0输液泵靶控输注异丙酚或氯胺酮 ,连接Aspect-A10 0 0型脑电监护仪监测脑电变化 ,观察两组患者血流动力学改变及麻醉恢复情况。结果 单用异丙酚患者随着异丙酚血药浓度升高脑电双频指数 (BIS)值降低 ,呈明显负相关 (P <0 0 5 ) ,氯胺酮血药浓度从 0 2 0mg/L增至 0 80mg/L ,BIS值无明显变化 (P >0 0 5 )。与P组相比 ,PK1,PK2 ,PK3 ,PK4组异丙酚用量减少约 15 %~ 40 % ,PK4组停药至睁眼时间明显延长 ,其余各组无明显差异 (P >0 0 5 )。术中P ,PK1组收缩压、舒张压升高 ,PK2 ,PK3 ,PK4组无明显改变。术后无躁动、不良回忆等并发症。结论 异丙酚复合镇痛剂量的氯胺酮 (0 40~ 0 60mg/L)靶控输注全静脉麻醉具有血流动力学稳定、减少异丙酚用量、无明显术后并发症等优点。 相似文献
108.
Lutz Fritsche Gunilla Einecke Franca Fleiner Duska Dragun Hans-Hellmut Neumayer Klemens Budde 《American journal of transplantation》2004,4(5):738-743
The reporting quality of publications of clinical trials can affect the quality of clinical decision-making. We systematically assessed the quality of publications of large multicenter trials evaluating immunosuppressive regimens in de novo kidney transplantation. Study quality, reporting quality and accessibility of the results of 63 publications were assessed independently by three blinded investigators using an instrument combining the Jadad scale with a list of reporting quality items. Study quality was rated with an average of only 2.3 (range 1-5) on the Jadad scale. Unblinded studies were reported in 68.3% of publications and follow-up longer than 12 months was reported for only 13 out of 50 studies. The reviewed publications fulfilled an average of 69.1% of the reporting quality criteria. Fifty-four percent of publications did not report both treated and biopsy-proven rejections. Whether reported graft survival was censored for death could not be determined for 27% of publications. Only a few publications gave confidence intervals (CIs) or stated whether additional analyses were pre-specified. Even the largest trials of immunosuppression in kidney transplantation show considerable quality deficits in their design and publication. Additional efforts are required of investigators, editors and sponsors to achieve maximum study and reporting quality. 相似文献
109.
Post-polio syndrome patients treated with intravenous immunoglobulin: a double-blinded randomized controlled pilot study 总被引:1,自引:1,他引:0
E. Farbu T. Rekand E. Vik-Mo H. Lygren N. E. Gilhus J. A. Aarli 《European journal of neurology》2007,14(1):60-65
Post-polio syndrome (PPS) is characterized by new muscle weakness, atrophy, fatigue and pain developing several years after the acute polio. Some studies suggest an ongoing inflammation in the spinal cord in these patients. From this perspective, intravenous immunoglobulin (IvIg) could be a therapeutic option. We performed a double-blinded randomized controlled pilot study with 20 patients to investigate the possible clinical effects of IvIg in PPS. Twenty patients were randomized to either IvIg 2 g/kg body weight or placebo. Primary endpoints were changes in pain, fatigue and muscle strength 3 months after treatment. Surrogate endpoints were changes in cerebrospinal fluid (CSF) cytokine levels. Secondary endpoints were pain, fatigue and isometric muscle strength after 6 months. Patients receiving IvIg reported a significant improvement in pain during the first 3 months, but no change was noted for subjective fatigue and muscle strength. CSF levels of tumour necrosis factor- α (TNF- α ) were increased compared with patients with non-inflammatory neurological disorders. In conclusion, in this small pilot study no effect was seen with IvIg treatment on muscle strength and fatigue, however IvIg treated PPS patients reported significantly less pain 3 months after treatment. TNF- α was increased in the CSF from PPS patients. The results are promising, but not conclusive because of the low number of patients studied. 相似文献
110.
Despite its place as the third leading cause of cancer deaths worldwide, there are currently no approved chemotherapeutic
agents, devices or techniques to treat hepatocellular carcinoma. Importantly, there have been no phase III studies demonstrating
survival benefit, nor any randomized studies of treatment except for transarterial chemoembolization and most recently sorafenib.
The importance of well-designed clinical trials of agents to treat HCC has never been greater. However, general clinical study
design issues, combined with HCC-specific issues pose significant challenges in structuring such studies. HCC-related challenges
include the heterogeneity of this cancer and the fact that it is frequently accompanied by significant comorbidities at diagnosis,
such as active hepatitis B or C virus replication, substantial past or on-going alcohol use, and cirrhosis, itself often a
fatal disease. The recently published comparison of a newer treatment, nolatrexed to doxorubicin, and comments about this
study’s initial HCC diagnostic criteria, staging system, comparator therapy and choice of endpoints have provided a platform
to discuss the challenges unique to the design of HCC clinical trials. The difficulty in accurately framing study results
obtained from the constantly changing HCC clinical landscape and approaches to meet these challenges will be reviewed. 相似文献